comparemela.com
4
5
6
7
8
9
10
Latest Breaking News On - Nivolumab - Page 3 : comparemela.com
SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Nottingham
United-kingdom
Lindy-durrant
University-of-nottingham
Academic-department-of-clinical-oncology
Academic-department
Clinical-oncology
Scib1
Nivolumab
Ipilimumab
Melanoma
Nivolumab Plus Cabozantinib in Non–Clear Cell RCC
David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.
Advanced-renal-cell-carcinoma
Plus-cabozantinib
Clear-cell
Advanced-rcc
Nrcc
Renal-cell-carcinoma
Non-clear-cell-rcc
Non-clear-cell-renal-carcinoma
Cabozantinib
Nivolumab
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Ohio
United-states
James-isaacs
Department-of-hematology
Medical-oncology
Cleveland-clinic
Cleveland-clinic-gross-family-melanoma-registry
Nivolumab
Talazoparib
Opdivo
Talzenna
Nivolumab-plus-talazoparib
When Does the PD-1 Inhibitor Come Before the Hedgehog Inhibitor for Neoadjuvant BCC/CSCC?
Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers.
Boston
Massachusetts
United-states
Washington
France
Stanford
California
Florida
Texas
Houston
University-of-california-san-francisco
Vishala-patel
Immunotherapy Before Noon Linked to Improved Survival in mRCC
Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.
Georgia
United-states
Database-consortium-risk-score
International-metastatic
Icis-at-winship-cancer-institute
Emory-winship-cancer-institute-in-atlanta
Winship-cancer-institute
Image-credit
Consortium-risk-score
Immunotherapy
Circadian-rhythm
vimarsana © 2020. All Rights Reserved.